KK
SPRY icon

KLP Kapitalforvaltning’s ARS Pharmaceuticals SPRY Stock Holding History

KLP Kapitalforvaltning’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.1K Hold
11,600
– – ﹤0.01% 2068
2025
Q4 		$135K Hold
11,600
– – ﹤0.01% 1979
2025
Q3 		$117K Hold
11,600
– – ﹤0.01% 2022
2025
Q2 		$202K Buy
11,600
+4,700
+68% +$67.8K ﹤0.01% 1780
2025
Q1 		$86.8K Hold
6,900
– – ﹤0.01% 2075
2024
Q4 		$72.8K Buy
+6,900
New +$96.6K ﹤0.01% 2182

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KLP Kapitalforvaltning's SPRY Position: Q1 2026 in Review

KLP Kapitalforvaltning held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 11,600 shares worth $93.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

KLP Kapitalforvaltning first reported a position in SPRY in Q4 2024 and has held it in 6 quarters since. The position peaked at $202K in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • KLP Kapitalforvaltning held 11,600 shares of ARS Pharmaceuticals worth $93.1K as of Q1 2026.
  • KLP Kapitalforvaltning left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q1 2026, its #2068 holding.
  • KLP Kapitalforvaltning first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • KLP Kapitalforvaltning's ARS Pharmaceuticals position peaked at $202K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q1 2026, filed 29 Apr 2026.